• Faron Pharmaceuticals entered agreement with Parexel to support upcoming randomized Phase IIb BEXERA trial in treatment-naïve higher-risk myelodysplastic syndromes.
• Collaboration targets disciplined trial execution to support timely delivery across North America and Europe.
• BEXERA trial is planned to start in second half of 2026.
• Study will test bexmarilimab at 1 mg/kg or 3 mg/kg with azacitidine versus placebo with azacitidine.
• Trial is expected to enroll 90 participants to select recommended Phase III dose and support later registrational filings in frontline HR-MDS.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faron Pharmaceuticals Oyj published the original content used to generate this news brief on April 16, 2026, and is solely responsible for the information contained therein.